Pay in 4 interest-free payments of $22.31 Learn more
Ships within 48 hours · Estimated delivery Aug 2 - Aug 7
PubMed PMID: 29523028
7178) joined by a linker to the estrogen-binding moiety 4-hydroxytamoxifen (Cat
Kozielski F
addition of the VEGFR-2 inhibitor NVP-ACC789 reduces BME cell number to baseline levels from 1 μM
Nilotinib (monohydrochloride monohydrate) - CAS# 923288-90-8 rasirox (Fe3+ chelate) PubMed PMID: 29523028Nilotinib, also known as AMN107, is a small molecule tyrosine kinase inhibitor approved for the treatment of imatinib resistant chronic myelogenous leukemia. Structurally related to imatinib, it was developed based on the structure of the Abl imatinib complex to address imatinib intolerance and resistance. Nilotinib is a selective Bcr Abl kinase inhibitor that is 10 30 fold more potent than imatinib in inhibiting Bcr Abl tyrosine kinase activity and